CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
一例难治性弥漫大 B 细胞淋巴瘤患者 CAR-T 治疗后经 18 F-FDG PET/CT 检出脾脏假性进展
英文原题：Splenic Pseudoprogression After CAR-T Therapy Detected by 18 F-FDG PET/CT in a Refractory Diffuse Large B-Cell Lymphoma Patient.
查看英文原题
Splenic Pseudoprogression After CAR-T Therapy Detected by 18 F-FDG PET/CT in a Refractory Diffuse Large B-Cell Lymphoma Patient.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
一名43岁女性被诊断为难治性弥漫大B细胞淋巴瘤，并转诊至本机构接受CAR-T 细胞治疗。经过3个周期桥接治疗后，输注前¹⁸F-FDG PET/CT提示完全代谢缓解。CAR-T 细胞输注1个月后进行的¹⁸F-FDG PET/CT显示脾脏有2处代谢活性增高灶，最终证实为假性进展。
展开英文摘要原文
A 43-year-old woman diagnosed with refractory diffuse large B-cell lymphoma was referred to chimeric antigen receptor T-cell therapy at our institution. After 3 cycles of bridging therapy, preinfusion 18 F-FDG PET/CT suggested a complete metabolic response. 18 F-FDG PET/CT 1 month after chimeric antigen receptor T-cell infusion showed 2 foci of elevated activity in the spleen, which was finally confirmed as pseudoprogression.
论文信息
- 作者
- Yao X、Wang H、Kan Y、Wang W、Yang J
- 单位
- From the Department of Nuclear Medicine, Beijing Friendship Hospital of Capital Medical University.China
- 文献类型
- 病例报告
- 期刊
- Clinical nuclear medicine2024 Aug 1
- 原文标识
- PubMed 38598485 · DOI 10.1097/RLU.0000000000005221